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Objective: Polypharmacy is widespread among older people, but the adverse outcomes associated with it
are unclear. We aim to synthesize current evidence on the adverse health, social, medicines manage-
ment, and health care utilization outcomes of polypharmacy in older people.
Design: A systematic review, of systematic reviews and meta-analyses of observational studies, was
conducted. Eleven bibliographic databases were searched from 1990 to February 2018. Quality was
assessed using AMSTAR (A Measurement Tool to Assess Systematic Reviews).
Setting and participants: Older people in any health care setting, residential setting, or country.
Results: Twenty-six reviews reporting on 230 unique studies were included. Almost all reviews oper-
ationalized polypharmacy as medication count, and few examined medication classes or disease states
within this. Evidence for an association between polypharmacy and many adverse outcomes, including
adverse drug events and disability, was conflicting. The most consistent evidence was found for hospi-
talization and inappropriate prescribing. No research had explored polypharmacy in the very old (aged
85 years), or examined the potential social consequences associated with medication use, such as
loneliness and isolation.
Conclusions and implications: The literature examining the adverse outcomes of polypharmacy in older
people is complex, extensive, and conflicting. Until polypharmacy is operationalized in a more clinically
relevant manner, the adverse outcomes associated with it will not be fully understood. Future studies
should work toward this approach in the face of rising multimorbidity and population aging.
 2019 AMDA e The Society for Post-Acute and Long-Term Care Medicine.Polypharmacy describes the situation where multiple medications
are prescribed for an individual, and it is most commonly defined as
the concomitant use of 5 or more medicines.1,2 Polypharmacy among
older people has become more common in recent years3,4 because of
disease-specific prescribing guidelines,5e7 rising levels of multi-
morbidity due to population ageing,7,8 and a lack of evidence to sup-
port deprescribing approaches.9 Indeed, the proportion of olderent research funded by the
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te and Long-Term Care Medicine.people taking 10 or more medicinesdso-called hyper-
polypharmacydmore than tripled between 1995 (4.9%) and 2010
(17.2%).3
Polypharmacy in older people may be appropriate7 but it also has
potential negative effects including reduced adherence, adverse drug
events, increased health care utilization, falls, cognitive impairment,
and mortality.10,11 The literature relating to polypharmacy has
expanded over the past 2 decades, with many groups exploring its
adverse outcomes through systematic review.12e14 Despite this prog-
ress and the growing literature base, the data relating to the spectrum
of polypharmacy-related adverse effects is conflicting in people aged
65 years, and even less clearly defined in the very old (aged
85 years), or across a range of health care and residential settings.
This is problematic as the very old are the fastest-growing section of
the population15,16 whose needs have the potential to reshape clinical
practice. In addition, polypharmacy is likely to generate more adverse
outcomes for older people, especially when combined with functional
decline, rising levels of multimorbidity, and frailty.17
L.E. Davies et al. / JAMDA 21 (2020) 181e187182It is, therefore, timely that we establish the consequences of pol-
ypharmacy in older people, so as to identify and target interventions
that may optimize prescribing-related outcomes in later life. The aim
of this study was to synthesize evidence from existing systematic
reviews on the adverse outcomes of polypharmacy in older people.
Methods
Protocol, Registration, and Study Design
To meet our aim, we employed a systematic review of systematic
reviews approach. This methodology builds a comprehensive picture
of a broad topic to inform policy, practice, patients, and the public.
The protocol for this review was registered with PROSPERO
(registration number: CRD42018088949). A PRISMA statement is also
included within the Supplementary Material 1.
Search Strategy
Eleven bibliographic databases were searched from 199018,19 to
February 2018 without language, setting, or geographical restrictions
(Supplementary Material 2). These included Database of Abstracts of
Reviews of Effects (DARE), Cochrane Database of Systematic Reviews
(CDSR), Health Technology Assessment Database (HTA), MEDLINE,
EMBASE, CINAHL, PsycINFO, Epistemonikos, PubMed, Scopus, and
Web of Science (SCI-Expanded, SSCI, CPCI-S, CPCI-SSH, ESCI). Gray
literature was searched via Google Scholar (first 300 results),20 TRIP,
NICE Evidence Search, and PROSPERO to reduce publication bias. Key
journals along with reference lists of included reviews were hand-
searched, and topic experts contacted to inquire about ongoing
studies. Titles and abstracts were screened by 1 reviewer (L.E.D.), and a
random sample of 10% screened by a second reviewer (G.S.). The full
texts of potentially relevant papers were then examined indepen-
dently by the 2 reviewers (L.E.D. and G.S.) and discrepancies resolved
through discussion.
Selection Criteria
Following standard evidence synthesis approaches, the inclusion
criteria for this review were determined a priori in terms of PICOS
(Population, Intervention, Comparison, Outcome and Study Design).
Population: older people from any health care or residential
setting. For the purposes of this review, we defined older people as
80% aged 55 years, or stratified data for the 55-year age group.
Intervention: polypharmacy (multiple medicines).2
Comparison: none.
Outcome: adverse health (eg, disability), social (eg, loneliness),
medicines management (eg, nonadherence) or health care utilization
outcomes (eg, hospital admission) of polypharmacy.
Study design: systematic reviews and/or meta-analyses of obser-
vational studies.
We excluded records that did not meet the quality standard (4
DARE criteria),21e23 did not consider the concept of polypharmacy, did
not relate adverse outcomes to polypharmacy, were not in older
people, or did not include observational studies. Irretrievable full texts
and randomized controlled trials or intervention studies were also
excluded.
Data Extraction
Information from eligible reviews was extracted by 1 reviewer
(L.E.D.) using a bespoke form adapted from the Cochrane Collabora-
tion24 (Supplementary Material 3) and a random sample of 10%
extracted by a second reviewer (G.S.). Extracted items included the
following: (1) first author, year of publication, search restrictions, anddatabases searched; (2) aim and review type; (3) primary study
design, setting, country, participant characteristics, and measures of
polypharmacy; and (4) outcomes, statistics, number of primary
studies, and number of participants (Supplementary Material 4). Re-
views were grouped under the adverse health, social, medicines
management, and health care utilization outcomes of polypharmacy,
with adverse health outcomes further categorized under geriatric
syndrome subheadings25,26 to help detect patterns in the data.27Quality Assessment
Quality assessment was performed independently by 2 reviewers
(L.E.D. and G.S.) using AMSTAR, and consensus reached through dis-
cussion.28 Included reviews had a median quality score of 4 (range 2-
6). Overall scores were presented under the categories of low (0-3),
medium (4-7), or high quality (8-11), alongside individual item scores
(Supplementary Material 5).29 No records were excluded following
quality assessment in order to present the evidence in context.Overlapping Primary Studies
Reviewswith overlapping primary studieswere removed30 to avoid
bias from double counting22,31 and provide a complete picture of the
relevant evidence fromwhich to examine conflicting findings.32 If 2 or
more reviews considered the same adverse outcome(s) from different
primary studies, all outcomes were reported. However, if 2 or more
reviews considered the same adverse outcome(s) from the same pri-
mary studies, we selected the most recent review.33 If this had low
AMSTAR quality, we proceeded to earlier review if it was of higher
AMSTAR quality and published within 5 years of the first.31 If the
excluded review reported additional adverse outcome(s) from unique
primary studies, these data were still reported so as to capture all
relevant evidence. When updated systematic reviews were encoun-
tered, only themost recent reviewwas included. The degree of overlap
was also presented using the Corrected Coverage Area Index (5.00%).34Data Synthesis
The adverse health, social, medicines management, and health
care utilization outcomes from each included review were presented
narratively with accompanying summary of evidence tables,18,22 for-
est plots, and harvest plots (Supplementary Materials 6-9). Summary
of evidence tables were annotated with the review number and
AMSTAR quality score.22 Forest plots were ordered by effect size to
highlight the strength of associations and aid the detection of het-
erogeneity.35 Outcomes were reported dependent on analytical
technique. Odds ratio, hazard ratio, relative risk, and b-coefficients
(95% confidence interval) were presented when single outcomes were
reported per review. When multiple results for the same adverse
outcomes were reported within the same review, the range of these
metrics was presented as a means to summarize the unsynthesized
heterogeneous information.
Harvest plots were used to highlight patterns, research gaps, and
publication bias within the narrative data, and reduce quantitative
bias.36,37 The height of each bar is proportional to the AMSTAR score,
with the number of primary studies and combined sample size
overlaid above to address discordance. These results were plotted
under categories of “no evidence,” “inverse association,” and “positive
effect” to avoid vote counting and value judgments.38
Both forest plots and harvest plots were annotatedwith the type of
observational study design per outcome, to highlight temporal
relationships.
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Fig. 1. PRISMA flow diagram of study selection.
L.E. Davies et al. / JAMDA 21 (2020) 181e187 183Patient and Public Involvement (PPI)
Six members of the Newcastle Universityesupported public and
patient engagement organization VOICE (Valuing Our Intellectual
Capital and Experience) with experience of polypharmacy discussed
the implications of this work in a specifically convened meeting.
Results
Study Selection and Characteristics
Twenty-six reviews reporting on 230 unique studies from North
America, Europe, Asia, and Australia, published between 2002 and
2018, were included (Figure 1). Five reviews12e14,39,40 had a
distinct polypharmacy focus and 21 contributed relevant data.
These 5 reviews operationalized polypharmacy as medication
count, and only 1 adequately examined medication classes within
this.39 Four reviews focused on specific conditionsdcancer, chronic
kidney disease, dementia, and Parkinson’s disease41e44dand 2
specific countries.45,46 Eleven reviews also reported the adverse
outcomes associated with specific medication classes,42,44,47e55 but
synthesis of this data was beyond the scope of this review. Sample
sizes ranged from 51 to more than 90,000, and participants were
aged from 16 to 108 years. Studies were included
from community,12,41,46,56,57 hospital,47,52e54,58e60 long-termcare facilities,39,51,55,61 home care,49 or a mixture of
settings.13,40,42e45,48,50 In 1 review, setting was not reported.14
Most reviews included studies of cross-sectional and longitudinal
design (Supplementary Material 4). Outcomes considered included
adverse health (n ¼ 16), health care utilization (n ¼ 11), medicines
management (n ¼ 7), and social consequences of polypharmacy
(n ¼ 1). Eighteen reviews40e48,51,52,54e59,61 reported 1
adverse outcome of polypharmacy and 8 reported multiple
outcomes.12e14,39,49,50,53,60Summary of Evidence Tables, Forest Plots, and Harvest Plots
Adverse Health Outcomes
Figure 2 summarizes the evidence for the adverse health outcomes
of polypharmacy, with more detailed information found within forest
plots and harvest plots (Supplementary Material 6). Positive associa-
tions were found for frailty, malnutrition, and selected chronic disease
areas. However, the evidence for adverse drug events, adverse drug
reactions, depression, cognitive impairment, falls, fractures, weight
loss, functional decline, disability, and mortality was conflicting.Adverse Social Outcomes
Evidence for the adverse social outcomes of polypharmacy was
sparse. One review reported a negative association between
Fig. 2. Summary of evidence for the adverse health outcomes of polypharmacy. The numbers in the figure refer to the numbered cited literature.
L.E. Davies et al. / JAMDA 21 (2020) 181e187184polypharmacy and physical activity participation in dementia
(Supplementary Material 7).41 No other potential social consequences
such as loneliness or isolation were reported.Adverse Medicines Management Outcomes
Medicines management describes the safe and effective use of
medicines by patients and the NHS in terms of prescribing, dispensing,
and administration. In this domain, 5 reviews13,43,46,49,61 reported
associations between polypharmacy and “service provider issues”
such as inappropriate prescribing. Three13,44,45 reported “patient
issues” such as nonadherence to medications (Figure 3 and
Supplementary Material 8).Adverse Health Care Utilization Outcomes
Polypharmacy was associated with many adverse health care uti-
lization outcomes including hospitalization, unplanned admissions,
and the number of prescribers (Figure 4 and Supplementary Material
9). However, the evidence for length of stay39,60 and nursing home
placement57,60 was conflicting.Discussion
Principal Findings
This review identified an extensive literature of conflicting evi-
dence for the association between polypharmacy and many adverse
outcomes including adverse drug reactions, adverse drug events, and
disability. A majority of reviews operationalized polypharmacy as
medication count, and of those that specifically focused on poly-
pharmacy,12e14,39,40 few adequately examined medication classes or
comorbidities.39 We identified a dearth of research exploring the
harms of polypharmacy in the very old (aged 85 years) and the
potential social consequences associated with it.
Comparison With Other Work
Our review identified many adverse outcomes of polypharmacy in
older people, in keeping with policy initiatives.62,63,64 However in
contrast to previous work,65,66 the evidence for an association with
adverse drug reactions and adverse drug events was conflicting,
which may reflect differences in appropriate vs inappropriate
 
  = quantitative and narrative data
Fig. 3. Summary of evidence for the adverse medicines management outcomes of polypharmacy. The numbers in the figure refer to the numbered cited literature.
L.E. Davies et al. / JAMDA 21 (2020) 181e187 185polypharmacy within the primary studies.7,67 The mixed picture sur-
rounding disability and functional decline is unsurprising, given the
lack of international consensus on their definition and measure-
ment.68 The evidence gap for the adverse social outcomes of poly-
pharmacy can be explained by the limited primary research in this
area,69,70 despite plausible pathways. For example, polypharmacymay
lead to loneliness and social isolation through cumulative side effects
that limit the ability to interact, such as impaired balance.12
Many of the associations between polypharmacy and symptoms
or diseases can be explained by the prevalence of different con-
ditions in later life and established patterns of prescribing. Circu-
latory, pulmonary, and endocrine diseases39 are, for example,Fig. 4. Summary of evidence for the adverse health care utilization outcomes of polypharma
reaction; RACF, residential aged care facility.commonly found in multimorbidity clusters in the very old.71
Other associations are more likely to reflect inappropriate pre-
scribing. Polypharmacy among residents of aged care facilities with
anxiety51 may be due to anxiolytic and hypnotic prescribing, for
example. We identified many adverse medicines management
outcomes of polypharmacy, notably, the association between pol-
ypharmacy and inappropriate prescribing in chronic kidney dis-
ease.43 The association between polypharmacy and an increased
risk of malnutrition12,13 is in keeping with a recent literature
review, with several drug classes implicated in drug-nutrient in-
teractions.72 The unclear evidence for body mass index and weight
loss may also suggest that malnutrition is a hidden problem among
cy. The numbers in the figure refer to the numbered cited literature. ADR, adverse drug
L.E. Davies et al. / JAMDA 21 (2020) 181e187186older people taking multiple medications. Polypharmacy and
frailty12,49 have been highlighted in recent UK clinical guidance,73
but the pathogenesis of this relationship is unclear,74 and we
could not determine how polypharmacy or specific drug classes
may influence frailty transitions. Our results appear to support the
widely held belief that polypharmacy is associated with admissions
to hospital, particularly unscheduled, and the number of pre-
scribers. However, the association between polypharmacy and
nursing home placement is unclear, and we could not determine
whether this conflicting evidence is related to long-term stays or
short-term admissions after hospital discharge.57,60 We found more
evidence supporting an association between polypharmacy and
mortality than not, with meta-analytic associations increasing with
medication count.40,60 However, confounding factors such as health
inequalities and specific anticholinergic medications may have
influenced this association.75,76
Strengths and Limitations
This was a comprehensive review, produced using established
methods.18,19,22,77 The use of data from observational studies allowed
us to explore the adverse outcomes of polypharmacy in “real world”
scenarios, and over longer time scales than is possible in randomized
controlled trials. Adverse outcomes were grouped in a novel matrix
and presented graphically to clearly communicate complex informa-
tion.38,78,79 PPI viewpoints helped to shape the interpretation of the
findings.
However, despite these strengths, we acknowledge that this
work has a number of limitations. First, as this was a review of
reviews, we did not search for, extract from, or assess the quality of
the original primary studies. Instead, we relied on information
provided by the authors of the included systematic reviews, but
acknowledge that reporting varied in style and quality. Most re-
views operationalized polypharmacy as multiple medicines, so we
could not draw the distinction between appropriate and inappro-
priate prescribing in terms of medication classes, indications, doses,
and durations. The measurement of polypharmacy through different
numerical cut-points also could have led to variable effect sizes. All
observational studies may be liable to confounding, and this is a
particular concern in reviews where polypharmacy was not the
main focus. Because of the challenges of residual confounding and
collinearity, polypharmacy could also be a proxy for morbidity. A
number of the reviews included cross-sectional studies that provide
no information on the direction of any associations. Their inclusion
is justified by our intention to produce a review of reviews that
could be a useful platform for further longitudinal research to
inform prescribing decisions. Several outcomes also came from a
small number of primary studies but were reported in line with our
review protocol. The influence of gender and socioeconomic posi-
tion on the adverse outcomes of polypharmacy were also seldom
studied. Lastly, the use of inconsistent or unclear measurement in-
struments for outcomes such as disability, cognitive impairment,
and depression reflects international variation, and limited cross-
study comparison.
Conclusions and Implications
The literature examining the adverse outcomes of polypharmacy in
older people is complex, extensive, and conflicting. The majority of
studies usedmedication counting as away of assessing polypharmacy,
which has the potential to aggregate very different medication and
disease profiles. Future work should seek to operationalize poly-
pharmacy in a more clinically relevant manner lest the adverse out-
comes associatedwith it, and deprescribing strategies, will not be fully
understood. At the very minimum, future studies of polypharmacyshould report medication classes and comorbidities to help untangle
conflicting associations and identify the medication and disease
clusters with the greatest risk of adverse outcomes. With this
approach, researchers should investigate medication utilization out-
comes in the very old (aged 85 years). Doing so is imperative in the
face of rising multimorbidity and population aging.
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